Local therapy combined with anti-PD-1 immunotherapy for advanced lung adenocarcinoma: A case report

J Cancer Res Ther. 2024 Apr 1;20(2):739-744. doi: 10.4103/jcrt.jcrt_1600_23. Epub 2024 Apr 30.

Abstract

Lung adenocarcinoma (LUAD) encompasses all lung epithelial cancers except small-cell lung cancer. Although programmed cell death protein 1 (PD-1) inhibitors, such as pembrolizumab, and other Food and Drug Administration-approved immune checkpoint inhibitors, offer new hope for LUAD treatment, LUAD's overall efficacy remains limited. Thus, the combination of immunotherapy with other therapeutic approaches has gained widespread attention. Local therapy is an optimal method for treating many advanced unresectable lung cancers. Herein, we present a case of a patient with multiple metastases from LUAD, who attained complete response for more than 3 years until present through local therapy combined with a PD-1 inhibitor.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma of Lung* / drug therapy
  • Adenocarcinoma of Lung* / immunology
  • Adenocarcinoma of Lung* / pathology
  • Adenocarcinoma of Lung* / therapy
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Combined Modality Therapy
  • Humans
  • Immune Checkpoint Inhibitors* / therapeutic use
  • Immunotherapy / methods
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / pathology
  • Lung Neoplasms* / therapy
  • Male
  • Middle Aged
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Treatment Outcome

Substances

  • Immune Checkpoint Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Programmed Cell Death 1 Receptor
  • pembrolizumab
  • PDCD1 protein, human